vs
CAL-MAINE FOODS INC（CALM）与UNITED THERAPEUTICS Corp（UTHR）财务数据对比。点击上方公司名可切换其他公司
UNITED THERAPEUTICS Corp的季度营收约是CAL-MAINE FOODS INC的1.0倍（$790.2M vs $769.5M），UNITED THERAPEUTICS Corp净利率更高（46.1% vs 13.4%，领先32.7%），UNITED THERAPEUTICS Corp同比增速更快（7.4% vs -19.4%），UNITED THERAPEUTICS Corp自由现金流更多（$173.3M vs $47.9M），过去两年CAL-MAINE FOODS INC的营收复合增速更高（29.4% vs 8.0%）
卡尔梅恩食品公司是总部位于美国密西西比州里奇兰的鲜蛋生产商，截至2024年是美国规模最大的蛋品企业。公司旗下拥有Egg-Land's Best、Land O'Lakes等多个知名蛋品品牌，1957年由弗雷德·R·亚当斯二世创立，亚当斯家族持有企业控股权，目前在纳斯达克挂牌上市。
United Therapeutics是美国生物技术企业，专注开发包含异种移植在内的器官移植相关药物与技术，多款产品布局肺部疾病及器官制造赛道，双总部位于马里兰州银泉与北卡罗来纳州三角研究园，在美加多地设有研发及运营分支机构。
CALM vs UTHR — 直观对比
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $769.5M | $790.2M |
| 净利润 | $102.8M | $364.3M |
| 毛利率 | 27.0% | 86.9% |
| 营业利润率 | 16.1% | 45.1% |
| 净利率 | 13.4% | 46.1% |
| 营收同比 | -19.4% | 7.4% |
| 净利润同比 | -53.1% | 20.9% |
| 每股收益（稀释后） | $2.13 | $7.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $769.5M | $790.2M | ||
| Q3 25 | $922.6M | $799.5M | ||
| Q2 25 | — | $798.6M | ||
| Q1 25 | $1.4B | $794.4M | ||
| Q4 24 | $954.7M | $735.9M | ||
| Q3 24 | $785.9M | $748.9M | ||
| Q2 24 | — | $714.9M | ||
| Q1 24 | $703.1M | $677.7M |
| Q4 25 | $102.8M | $364.3M | ||
| Q3 25 | $199.3M | $338.7M | ||
| Q2 25 | — | $309.5M | ||
| Q1 25 | $508.5M | $322.2M | ||
| Q4 24 | $219.1M | $301.3M | ||
| Q3 24 | $150.0M | $309.1M | ||
| Q2 24 | — | $278.1M | ||
| Q1 24 | $146.7M | $306.6M |
| Q4 25 | 27.0% | 86.9% | ||
| Q3 25 | 33.7% | 87.4% | ||
| Q2 25 | — | 89.0% | ||
| Q1 25 | 50.5% | 88.4% | ||
| Q4 24 | 37.3% | 89.7% | ||
| Q3 24 | 31.5% | 88.9% | ||
| Q2 24 | — | 89.1% | ||
| Q1 24 | 31.1% | 89.2% |
| Q4 25 | 16.1% | 45.1% | ||
| Q3 25 | 27.0% | 48.6% | ||
| Q2 25 | — | 45.6% | ||
| Q1 25 | 44.8% | 48.2% | ||
| Q4 24 | 29.1% | 48.6% | ||
| Q3 24 | 23.8% | 45.8% | ||
| Q2 24 | — | 44.7% | ||
| Q1 24 | 23.2% | 52.6% |
| Q4 25 | 13.4% | 46.1% | ||
| Q3 25 | 21.6% | 42.4% | ||
| Q2 25 | — | 38.8% | ||
| Q1 25 | 35.9% | 40.6% | ||
| Q4 24 | 22.9% | 40.9% | ||
| Q3 24 | 19.1% | 41.3% | ||
| Q2 24 | — | 38.9% | ||
| Q1 24 | 20.9% | 45.2% |
| Q4 25 | $2.13 | $7.66 | ||
| Q3 25 | $4.12 | $7.16 | ||
| Q2 25 | — | $6.41 | ||
| Q1 25 | $10.38 | $6.63 | ||
| Q4 24 | $4.47 | $6.23 | ||
| Q3 24 | $3.06 | $6.39 | ||
| Q2 24 | — | $5.85 | ||
| Q1 24 | $3.00 | $6.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $369.4M | $2.9B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.7B | $7.1B |
| 总资产 | $3.1B | $7.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $369.4M | $2.9B | ||
| Q3 25 | $251.9M | $2.8B | ||
| Q2 25 | — | $3.0B | ||
| Q1 25 | $497.2M | $3.3B | ||
| Q4 24 | $140.3M | $3.3B | ||
| Q3 24 | $181.7M | $3.3B | ||
| Q2 24 | — | $3.0B | ||
| Q1 24 | $367.1M | $2.7B |
| Q4 25 | $2.7B | $7.1B | ||
| Q3 25 | $2.7B | $6.6B | ||
| Q2 25 | — | $7.2B | ||
| Q1 25 | $2.4B | $6.8B | ||
| Q4 24 | $2.0B | $6.4B | ||
| Q3 24 | $1.9B | $6.1B | ||
| Q2 24 | — | $5.7B | ||
| Q1 24 | $1.7B | $5.3B |
| Q4 25 | $3.1B | $7.9B | ||
| Q3 25 | $3.2B | $7.4B | ||
| Q2 25 | — | $7.9B | ||
| Q1 25 | $3.1B | $7.7B | ||
| Q4 24 | $2.5B | $7.4B | ||
| Q3 24 | $2.4B | $7.1B | ||
| Q2 24 | — | $6.7B | ||
| Q1 24 | $2.1B | $6.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $94.8M | $346.2M |
| 自由现金流经营现金流 - 资本支出 | $47.9M | $173.3M |
| 自由现金流率自由现金流/营收 | 6.2% | 21.9% |
| 资本支出强度资本支出/营收 | 6.1% | 21.9% |
| 现金转化率经营现金流/净利润 | 0.92× | 0.95× |
| 过去12个月自由现金流最近4个季度 | $895.9M | $1.0B |
8季度趋势，按日历期对齐
| Q4 25 | $94.8M | $346.2M | ||
| Q3 25 | $278.6M | $562.1M | ||
| Q2 25 | — | $191.7M | ||
| Q1 25 | $571.6M | $461.2M | ||
| Q4 24 | $122.7M | $341.2M | ||
| Q3 24 | $117.5M | $377.2M | ||
| Q2 24 | — | $232.2M | ||
| Q1 24 | $164.0M | $376.5M |
| Q4 25 | $47.9M | $173.3M | ||
| Q3 25 | $233.3M | $351.6M | ||
| Q2 25 | — | $129.5M | ||
| Q1 25 | $521.8M | $386.3M | ||
| Q4 24 | $92.9M | $254.5M | ||
| Q3 24 | $81.7M | $300.7M | ||
| Q2 24 | — | $187.1M | ||
| Q1 24 | $133.8M | $338.3M |
| Q4 25 | 6.2% | 21.9% | ||
| Q3 25 | 25.3% | 44.0% | ||
| Q2 25 | — | 16.2% | ||
| Q1 25 | 36.8% | 48.6% | ||
| Q4 24 | 9.7% | 34.6% | ||
| Q3 24 | 10.4% | 40.2% | ||
| Q2 24 | — | 26.2% | ||
| Q1 24 | 19.0% | 49.9% |
| Q4 25 | 6.1% | 21.9% | ||
| Q3 25 | 4.9% | 26.3% | ||
| Q2 25 | — | 7.8% | ||
| Q1 25 | 3.5% | 9.4% | ||
| Q4 24 | 3.1% | 11.8% | ||
| Q3 24 | 4.6% | 10.2% | ||
| Q2 24 | — | 6.3% | ||
| Q1 24 | 4.3% | 5.6% |
| Q4 25 | 0.92× | 0.95× | ||
| Q3 25 | 1.40× | 1.66× | ||
| Q2 25 | — | 0.62× | ||
| Q1 25 | 1.12× | 1.43× | ||
| Q4 24 | 0.56× | 1.13× | ||
| Q3 24 | 0.78× | 1.22× | ||
| Q2 24 | — | 0.83× | ||
| Q1 24 | 1.12× | 1.23× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CALM
| Retail | $625.4M | 81% |
| Prepared Foods | $71.7M | 9% |
| Egg Products | $34.5M | 4% |
| Service Other | $19.2M | 2% |
| Other | $13.8M | 2% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
